Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by Boomskidon Sep 30, 2023 12:17pm
112 Views
Post# 35663271

RE:RE:RE:RE:RE:I sure like this Jon

RE:RE:RE:RE:RE:I sure like this JonIn all the material I've studied, G1945V, there has been no concern expressed about the transport of bacteria, viruses or other material across the BBB through receptor mediated transcytosis (RMT) once the receptor is populated with its intended ligand.

Some viruses can enter cells through receptor mediated endocytosis but that happens in competition with other ligands and not in concert with them. The smallest viral particles are about the same size as the largest proteins. I've never read anywhere that a virus can attach itself to a protein and be carried into a cell as an attachment to the protein. 

The medically attractive nature of RMT is that it does not disrupt the BBB. Receptors are very selective and allow the transport of matching proteins. I think you've asked a good question but it may be a stretch to think that disease risks would be increased with xB3 RMT. I think it more likely that off-target issues with the LRP-1 receptors in the CNS would be a bigger issue.

This is a stretch opinion on my part. To my knowledge, Denali has never discussed it as a problem and I've never had cause to directly study the question. Certainly, if Bioasis knew there were problems of this or any other mature, they should be discussing it in their filings regarding the potential risks associated with xB3.

jd
<< Previous
Bullboard Posts
Next >>